e-Drug3D

2161

SUNVOZERTINIB

INN
SUNVOZERTINIB

cas 2370013-12-8

CLASS

ANTINEOPLASTIC
EGFR KINASE INHIBITOR
TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 6 HOUR
VD 2116 LITER
Cl 29 LITER / HOUR
PPB 91 PERCENT
t1/2 50 HOUR

Target

TARGET EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)

DrugCentral

Download SDF file

2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]- (ACI)

Formula:
C29H35ClFN7O3

Calculated chemical properties:

MW 584.09
NB_atoms 41
XLogP 5.26
PSA 105.211
NB_HD 4
NB_HA 10
fsp3 0.34
Lipinski(0=no;1=yes) 0

FDA
NDA 219839 (pdf not found) INN (SUNVOZERTINIB) ZEGFROVY (DIZAL JIANGSU) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY